Actinium Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>AP</div>
ATNM -- USA Stock  

USD 10.89  0.07  0.64%

It appears without question that Actinium Pharmaceuticals may not have a good chance to recover from the new pull down as its shares fell again. The company's current daily volatility is 5.76 percent, with a beta of 0.54 and an alpha of -0.66 over DOW. As many millenniums are trying to avoid the new volatility, we are going to summarize Actinium Pharmaceuticals a little further to understand its historical price patterns. Why are we still confident in our projection for a recovery.
Published over three weeks ago
View all stories for Actinium Pharmaceuticals | View All Stories
Is Actinium Pharmaceuticals (NYSEMKT:ATNM) a new disruptor?
This firm conducts business under Healthcare sector and is part of Biotechnology industry. The firm shows a Beta (market volatility) of 0.5387, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Actinium's beta means in this case. As returns on the market increase, Actinium Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Actinium Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Actinium Pharmaceuticals historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Actinium Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate its performance. Actinium Pharmaceuticals has an expected return of -0.73%. Please be advised to confirm Actinium Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Actinium Pharmaceuticals stock performance from the past will be repeated at some point in the near future.
Investing in Actinium Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Actinium Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Actinium Pharmaceuticals's Liquidity

Actinium Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Actinium Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Actinium Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Actinium Pharmaceuticals's total debt and its cash.

How Actinium utilizes its cash?

To perform a cash flow analysis of Actinium Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Actinium Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Actinium Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Actinium Pharmaceuticals Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (23.16 Million)

Actinium Pharmaceuticals Correlation with Peers

Investors in Actinium can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Actinium Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Actinium Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Actinium is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Actinium for more details

Breaking it down a bit more

Actinium Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had -0.13% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Actinium Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Actinium Pharmaceuticals risk adjusted performance of (0.12), and Mean Deviation of 4.16 to double-check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Our Actinium analysis denotes possible reversion in December

The total risk alpha is down to -0.7 as of today. Actinium Pharmaceuticals exhibits very low volatility with skewness of -1.23 and kurtosis of 4.06. However, we advise investors to further study Actinium Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

The Current Takeaway on Actinium Pharmaceuticals Investment

While some firms in the biotechnology industry are either recovering or due for a correction, Actinium Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. While some stakeholders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Actinium Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Actinium Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com